Related Experiment Video

Updated: Oct 24, 2025

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

4.2K

The relationship between hepatic fibrosis and arterial stiffness in hemodialysis patients

Fatma Betul Guzel1, Ilyas Ozturk2, Kadir Gisi3

  • 1Internal Medicine Department, Kahramanmaraş Necip Fazil City Hospital, Kahramanmaraş, Turkey.

Seminars in Dialysis
|August 14, 2021
PubMed

Insights

Hepatic fibrosis is linked to increased arterial stiffness in hemodialysis patients. This finding highlights a potential connection between liver health and cardiovascular risk in this population.

Area of Science:

  • Nephrology
  • Cardiology
  • Hepatology

Background:

  • Cardiovascular diseases are the leading cause of mortality in hemodialysis patients.
  • Arterial stiffness is a known predictor of cardiovascular events in hemodialysis patients.
  • Hepatic fibrosis and nonalcoholic fatty liver disease are associated with increased arterial stiffness in the general population.

Purpose of the Study:

  • To investigate the relationship between hepatic fibrosis and arterial stiffness in patients undergoing chronic hemodialysis.
  • To explore potential links between liver health and vascular function in end-stage renal disease.

Main Methods:

  • Study included 59 adult chronic hemodialysis patients with a minimum 6-month treatment duration.
  • Exclusion criteria included chronic liver disease, viral hepatitis, alcohol use, and other specific conditions.
  • Hepatic fibrosis was assessed using FibroScan, and arterial stiffness was measured by pulse wave velocity (PWV) using Mobil-o-Graph.

Main Results:

  • The average PWV was 8.3 ± 1.6 m/s, positively correlated with age, CAP score, fibrosis score, and BMI, and negatively correlated with albumin.
  • Patients with PWV ≥ 10 m/s exhibited significantly higher CAP scores compared to those with PWV < 10 m/s.
  • Regression analysis identified age and systolic blood pressure as determinants of PWV.

Conclusions:

  • Increased hepatic fibrosis in hemodialysis patients is associated with elevated arterial stiffness.
  • This association, while present, was not found to be independent in the studied cohort.
Abstract

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K
Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy10:35

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy

Published on: October 19, 2016

10.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
36
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
482
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
203
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
37
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
246
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
38